BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARalpha agonist. It reduces lipogenesis by inhibiting synthesis and promoting excretion. BGT-002 has demonstrated efficacy in vivo for improving metabolic dysfunction-associated steatohepatitis (MASH) and alleviating hyperlipidemia. It is applicable for research on hypercholesterolemia and MASH.
Molekulargewicht:
326.48
CAS Nummer:
[2127387-94-2]
Formel:
C19H34O4
Target-Kategorie:
ATP Citrate Lyase|||PPAR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
